When is the next results date for Bandaram Pharma?

No Upcoming Board Meetings

Who are in the management team of Bandaram Pharma?

As of March 2018, the management team of Bandaram Pharma includes Chairman Kishan Prasad Palayu, Non Executive Directors Mahesh Kumar Vellaboyina and Sangam Venkateshwar Rao, Non Executive Independent Director Namrata Chadha, and Executive Director Shivarama Babu Velchuri, who receives a remuneration of 36.0 lacs.

As of March 2018, the management team of Bandaram Pharma includes:<BR><BR>- Kishan Prasad Palayu, who serves as the Chairman.<BR>- Mahesh Kumar Vellaboyina, who is a Non Executive Director.<BR>- Sangam Venkateshwar Rao, also a Non Executive Director.<BR>- Namrata Chadha, who holds the position of Non Executive Independent Director.<BR>- Shivarama Babu Velchuri, who is the Executive Director.<BR><BR>Shivarama Babu Velchuri is noted to receive a remuneration of 36.0 lacs.

Has Bandaram Pharma declared dividend?

Bandaram Pharma Packtech Ltd has declared a 1% dividend, amounting to 0.1 per share, with an ex-date of September 20, 2024. Total returns have varied significantly across periods, with a 5-year total return of 166.14%, despite some shorter periods showing negative returns.

Bandaram Pharma Packtech Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -15.87%, with a dividend return of 0%, resulting in a total return of -15.87%.<BR><BR>Over the 1-year period, the price return was 7.69%, the dividend return was 0.30%, leading to a total return of 7.99%.<BR><BR>For the 2-year period, the price return was -49.75%, with no dividend return, resulting in a total return of -49.75%.<BR><BR>In the 3-year period, the price return was 0%, and there was no dividend return, leading to a total return of 0.0%.<BR><BR>During the 4-year period, the price return was 165.45%, with no dividend return, resulting in a total return of 165.45%.<BR><BR>For the 5-year period, the price return was 165.45%, with a dividend return of 0.69%, leading to a total return of 166.14%.<BR><BR>Overall, while Bandaram Pharma has declared a dividend, the total returns over various periods show significant variability, with some periods reflecting substantial gains, particularly over the longer term, despite certain periods showing negative returns.

Who are the peers of the Bandaram Pharma?

Bandaram Pharma's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and others, with varying management risks and growth rates. Poly Medicure leads in 1-year returns at 24.29%, while Bandaram Pharma has a return of 14.84%.

Peers: Bandaram Pharma's peers are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, KMS Medisurgi, and Medinova Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent for Bandaram Pharma, Average for Poly Medicure, Indegene, and the rest, while Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, KMS Medisurgi, and the rest. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Below Average or Good capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while the lowest is Amkay Products at -34.33%. Bandaram Pharma's 1-year return is 14.84%, which is significantly higher than Amkay Products but lower than Poly Medicure. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, and Amkay Products.

What is the technical trend for Bandaram Pharma?

As of May 5, 2025, Bandaram Pharma's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and moving averages, alongside a bearish monthly RSI.

As of 5 May 2025, the technical trend for Bandaram Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside a bearish reading from the daily moving averages. The monthly RSI also indicates bearish momentum, while the KST and Dow Theory show mildly bearish conditions on a monthly basis. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Bandaram Pharma.

What does Bandaram Pharma do?

Bandaram Pharma Packtech Ltd is a micro-cap company in the healthcare services industry, focusing on the processing and supply of recycled paper. It was incorporated in 1991 and transitioned to this focus in 2022, reporting net sales of 85 Cr and a net profit of 2 Cr as of March 2025.

Overview:<BR>Bandaram Pharma Packtech Ltd operates in the healthcare services industry, focusing on the processing and supply of recycled paper, and is categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated on December 2, 1991, Bandaram Pharma Packtech Ltd was originally established to manufacture latex gloves. The company later diversified into the paper industry in 2022. As of the latest quarterly results reported for March 2025, the company has transitioned to solely focusing on recycled paper.<BR><BR>Financial Snapshot:<BR>Net Sales: 85 Cr (Quarterly Results - Mar 2025)<BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025)<BR>Market Cap: INR 48 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 48.00<BR>Industry P/E: 53<BR>Dividend Yield: 0.05%<BR>Debt-Equity: 1.35<BR>Return on Equity: 7.83%<BR>Price to Book: 3.77<BR><BR>Contact Details:<BR>Address: 601 5th Floor Oxford Towers, Old Airport Road Kodihalli Bangalore Karnataka : 560008<BR>Email: contact@shivamedicare.com<BR>Website: http://www.bandaram.com

Who are the top shareholders of the Bandaram Pharma?

The top shareholder of Bandaram Pharma is B. Deepak Reddy, holding 39.38% of the shares, with no pledged promoter holdings. The highest public shareholder is Sanivarapu Jhansi at 6.54%, while individual investors collectively own 23.74%.

The top shareholders of Bandaram Pharma include the promoters, with B. Deepak Reddy holding the largest stake at 39.38%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanivarapu Jhansi, who owns 6.54% of the shares. Additionally, individual investors collectively hold 23.74% of the company's shares.

How big is Bandaram Pharma?

As of 24th July, Bandaram Pharma Packtech Ltd has a market capitalization of 46.00 Cr, with recent net sales of 36.97 Cr and a net profit of 0.99 Cr. The latest balance sheet shows shareholder's funds of 12.28 Cr and total assets of 32.06 Cr.

As of 24th July, Bandaram Pharma Packtech Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 36.97 Cr and a Net Profit of 0.99 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 12.28 Cr and Total Assets of 32.06 Cr.

Are Bandaram Pharma latest results good or bad?

Bandaram Pharma's latest results are disappointing, with a 28.76% decline in net sales and the lowest profit before tax in five quarters. The stock is currently rated as a 'Strong Sell,' indicating a negative outlook for the company.

Bandaram Pharma's latest results are quite disappointing. For the quarter ending June 2025, the company reported net sales of Rs 8.10 crore, which represents a significant year-on-year decline of 28.76%. This sharp drop in sales is concerning and indicates a troubling trend in their financial performance.<BR><BR>Moreover, the profit before tax, excluding other income, was only Rs 0.04 crore, marking the lowest figure the company has seen in the past five quarters. This decline in profitability, alongside a deteriorating financial score that dropped to -6, suggests that the company's financial health is worsening.<BR><BR>Additionally, the current stock call for Bandaram Pharma is classified as a 'Strong Sell,' reflecting the challenges the company is facing in the market. Overall, these results indicate a negative outlook for Bandaram Pharma at this time.

Is Bandaram Pharma overvalued or undervalued?

As of November 28, 2025, Bandaram Pharma is considered overvalued with a PE ratio of 216.00 and a valuation grade of attractive, despite strong short-term returns, due to negative year-to-date and one-year performance.

As of 28 November 2025, Bandaram Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its worth. The company is currently considered overvalued, with a PE ratio of 216.00, a Price to Book Value of 3.71, and an EV to EBITDA of 30.28. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bandaram Pharma's PE ratio is significantly higher than Lenskart Solutions at 241.34 and Poly Medicure at 54.51, both of which are also considered expensive. The PEG ratio of 51.30 further emphasizes the overvaluation, especially when compared to the industry standards. While Bandaram Pharma has shown strong short-term returns, outperforming the Sensex in the past week and month, its year-to-date and one-year returns are negative, which adds to the concern regarding its current valuation.

How has been the historical performance of Bandaram Pharma?

Bandaram Pharma has shown steady growth in net sales and profit over the past three years, with net sales increasing from 18.73 Cr in Mar'23 to 36.96 Cr in Mar'25, and profit after tax rising from 0.26 Cr to 0.99 Cr. Total assets and liabilities also grew significantly during this period, while cash flow from operating activities remained negative but stable.

Answer:<BR>The historical performance of Bandaram Pharma shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Bandaram Pharma's net sales increased from 18.73 Cr in Mar'23 to 34.08 Cr in Mar'24, and further to 36.96 Cr in Mar'25, indicating a consistent upward trend. Total operating income mirrored this growth, reaching 36.96 Cr in Mar'25. The total expenditure also rose, from 17.57 Cr in Mar'23 to 34.14 Cr in Mar'25, primarily driven by raw material costs and employee expenses. Operating profit (PBDIT) improved from 1.35 Cr in Mar'23 to 2.91 Cr in Mar'25, while profit before tax rose from 0.33 Cr to 1.32 Cr in the same period. Profit after tax followed suit, increasing from 0.26 Cr in Mar'23 to 0.99 Cr in Mar'25. The company's total assets grew significantly from 20.17 Cr in Mar'23 to 38.92 Cr in Mar'25, alongside total liabilities which increased from 20.17 Cr to 38.92 Cr. Cash flow from operating activities remained negative but stable at -4.00 Cr in both Mar'24 and Mar'25, while cash flow from financing activities showed a positive trend, reaching 5.00 Cr in Mar'25. Overall, Bandaram Pharma has demonstrated solid growth in sales and profitability, alongside an increase in both assets and liabilities.

Should I buy, sell or hold Bandaram Pharma?

Which are the latest news on Bandaram Pharma?

Why is Bandaram Pharma falling/rising?

As of 04-Dec, Bandaram Pharma Packtech Ltd's stock price is at Rs 36.58, down 4.99% and part of a three-day decline totaling 23.02%. The stock has underperformed its sector and experienced a significant drop in investor participation, contributing to its current downward trend.

As of 04-Dec, Bandaram Pharma Packtech Ltd's stock price is falling, currently at Rs 36.58, which reflects a decrease of Rs 1.92 or 4.99%. This decline is part of a broader trend, as the stock has been losing value for the last three days, resulting in a total drop of 23.02% during this period. Today, the stock opened with a loss of 4.99%, reaching an intraday low of Rs 36.58, and has not traded outside this price range.<BR><BR>Additionally, the stock has underperformed its sector by 4.68% today, indicating weaker performance relative to its peers. Investor participation has also decreased significantly, with a delivery volume of only 2.47k on December 3, which is down by 89.79% compared to the 5-day average delivery volume. This lack of investor interest may contribute to the downward pressure on the stock price.<BR><BR>While the stock has shown positive returns over the past week and month, with increases of 10.85% and 49.67% respectively, its year-to-date performance remains negative at -17.61%. Overall, the combination of recent consecutive declines, reduced trading volume, and underperformance against the sector are key factors contributing to the stock's current falling price.